

UNITED STATES BANKRUPTCY COURT

DISTRICT OF Delaware

In re: Insys Therapeutics, Inc.,

§
§
§
§

Case No. 19-11292

Debtor(s)

☐ Jointly Administered

Post-confirmation Report

Chapter 11

Quarter Ending Date: 03/31/2026

Petition Date: 06/10/2019

Plan Confirmed Date: 01/16/2020

Plan Effective Date: 02/18/2020

This Post-confirmation Report relates to: ☐ Reorganized Debtor

☒ Other Authorized Party or Entity: Insys Liquidation Trust

Name of Authorized Party or
Entity

/s/ Lige Gu

Signature of Responsible Party

04/14/2026

Date

Lige Gu

Printed Name of Responsible Party

Halperin Battaglia Benzija, LLP
40 Wall Street, 37th Floor
New York, NY 10005

Address

STATEMENT: This Periodic Report is associated with an open bankruptcy case; therefore, Paperwork Reduction Act exemption 5 C.F.R. § 1320.4(a)(2) applies.

Debtor's Name Insys Therapeutics, Inc.,

Case No. 19-11292

Part 1: Summary of Post-confirmation Transfers

	Current Quarter	Total Since Effective Date
a. Total cash disbursements	\$215,642	\$29,834,238
b. Non-cash securities transferred	\$0	\$0
c. Other non-cash property transferred	\$0	\$0
d. Total transferred (a+b+c)	\$215,642	\$29,834,238

Part 2: Preconfirmation Professional Fees and Expenses

a.			Approved Current	Approved Cumulative	Paid Current Quarter	Paid Cumulative	
	Professional fees & expenses (bankruptcy) incurred by or on behalf of the debtor <i>Aggregate Total</i>		\$0	\$0	\$0	\$10,199,965	
	<i>Itemized Breakdown by Firm</i>						
		Firm Name	Role				
	i	ALTO Litigation	Special Counsel	\$0	\$0	\$0	\$2,838
	ii	Andersen Tax	Financial Professional	\$0	\$0	\$0	\$60,664
	iii	Carlton Fields	Other	\$0	\$0	\$0	\$435,811
	iv	Columbus	Other	\$0	\$0	\$0	\$3,900
	v	Dinsmore & Shohi	Special Counsel	\$0	\$0	\$0	\$4,538
	vi	DLA Piper	Special Counsel	\$0	\$0	\$0	\$3,942
	vii	Ernst & Young	Financial Professional	\$0	\$0	\$0	\$5,200
	viii	Epiq	Other	\$0	\$0	\$0	\$1,124,069
	ix	FTI Consulting	Financial Professional	\$0	\$0	\$0	\$3,891,025
	x	Gibbons	Special Counsel	\$0	\$0	\$0	\$8,525
	xi	Hampton Barghois Pierce	Special Counsel	\$0	\$0	\$0	\$3,483
	xii	Holland & Knight	Special Counsel	\$0	\$0	\$0	\$120,436
	xiii	Lazard Freres	Financial Professional	\$0	\$0	\$0	\$1,478,864
	xiv	Miller Friel	Special Counsel	\$0	\$0	\$0	\$69,684
	xv	Rakoczy Molion Mazzochi	Special Counsel	\$0	\$0	\$0	\$5,917
	xvi	Resolutions Inc.	Special Counsel	\$0	\$0	\$0	\$25,000
	xvii	Richards Layton & Finger	Special Counsel	\$0	\$0	\$0	\$1,018,507
	xviii	Rose Law Firm	Special Counsel	\$0	\$0	\$0	\$3,617
	xix	Shook Hardy & Bacon	Special Counsel	\$0	\$0	\$0	\$543
	xx	Spiro Harrison	Special Counsel	\$0	\$0	\$0	\$45,839
	xxi	Squire Patton Boggs	Special Counsel	\$0	\$0	\$0	\$354
	xxii	Weil Gotshal & Manges	Lead Counsel	\$0	\$0	\$0	\$1,759,519
	xxiii	Wilson Sonsini Goodrich & Ros	Special Counsel	\$0	\$0	\$0	\$127,690
xxiv							
xxv							
xxvi							
xxvii							
xxviii							
xxix							

Debtor's Name Insys Therapeutics, Inc.,

Case No. 19-11292

xxx						
xxxi						
xxxii						
xxxiii						
xxxiv						
xxxv						
xxxvi						
xxxvii						
xxxviii						
xxxix						
xl						
xli						
xlii						
xliii						
xliv						
xlv						
xlvi						
xlvii						
xlviii						
xlix						
l						
li						
lii						
liii						
liv						
lv						
lvi						
lvii						
lviii						
lix						
lx						
lxi						
lxii						
lxiii						
lxiv						
lxv						
lxvi						
lxvii						
lxviii						
lxix						
lxx						
lxxi						

b.				Approved Current	Approved Cumulative	Paid Current Quarter	Paid Cumulative
	Professional fees & expenses (nonbankruptcy) incurred by or on behalf of the debtor <i>Aggregate Total</i>						
	<i>Itemized Breakdown by Firm</i>						
		Firm Name	Role				
	i						
	ii						
	iii						
	iv						
	v						
	vi						

Debtor's Name Insys Therapeutics, Inc.,

Case No. 19-11292

vii						
viii						
ix						
x						
xi						
xii						
xiii						
xiv						
xv						
xvi						
xvii						
xviii						
xix						
xx						
xxi						
xxii						
xxiii						
xxiv						
xxv						
xxvi						
xxvii						
xxviii						
xxix						
xxx						
xxxi						
xxxii						
xxxiii						
xxxiv						
xxxv						
xxxvi						
xxxvii						
xxxviii						
xxxix						
xl						
xli						
xlii						
xliii						
xliv						
xlv						
xlvi						
xlvii						
xlviii						

Debtor's Name Insys Therapeutics, Inc.,

Case No. 19-11292

xlix						
l						
li						
lii						
liii						
liv						
lv						
lvi						
lvii						
lviii						
lix						
lx						
lxi						
lxii						
lxiii						
lxiv						
lxv						
lxvi						
lxvii						
lxviii						
lxix						
lxx						
lxxi						
lxxii						
lxxiii						
lxxiv						
lxxv						
lxxvi						
lxxvii						
lxxviii						
lxxix						
lxxx						
lxxxi						
lxxxii						
lxxxiii						
lxxxiv						
lxxxv						
lxxxvi						
lxxxvii						
lxxxviii						
lxxxix						
xc						

Debtor's Name Insys Therapeutics, Inc.,

Case No. 19-11292

	xcii						
	xciii						
	xciv						
	xcv						
	xcvi						
	xcvii						
	xcviii						
	xcix						
	c						
	ci						
c.	All professional fees and expenses (debtor & committees)					\$0	\$11,876,616

Part 3: Recoveries of the Holders of Claims and Interests under Confirmed Plan

	Total Anticipated Payments Under Plan	Paid Current Quarter	Paid Cumulative	Allowed Claims	% Paid of Allowed Claims
a. Administrative claims	\$0	\$0	\$705,413	\$705,413	100%
b. Secured claims	\$0	\$0	\$0	\$0	0%
c. Priority claims	\$0	\$0	\$165,597	\$165,597	100%
d. General unsecured claims	\$0	\$0	\$0	\$0	0%
e. Equity interests	\$0	\$0	\$0		

Part 4: Questionnairea. Is this a final report? Yes ☐ No ☒

If yes, give date Final Decree was entered: _____

If no, give date when the application for Final Decree is anticipated: _____

b. Are you current with quarterly U.S. Trustee fees as set forth under 28 U.S.C. § 1930? Yes ☒ No ☐

Debtor's Name Insys Therapeutics, Inc.,

Case No. 19-11292

Privacy Act Statement

28 U.S.C. § 589b authorizes the collection of this information and provision of this information is mandatory. The United States Trustee will use this information to calculate statutory fee assessments under 28 U.S.C. § 1930(a)(6) and to otherwise evaluate whether a reorganized chapter 11 debtor is performing as anticipated under a confirmed plan. Disclosure of this information may be to a bankruptcy trustee when the information is needed to perform the trustee's duties, or to the appropriate federal, state, local, regulatory, tribal, or foreign law enforcement agency when the information indicates a violation or potential violation of law. Other disclosures may be made for routine purposes. For a discussion of the types of routine disclosures that may be made, you may consult the Executive Office for United States Trustee's systems of records notice, UST-001, "Bankruptcy Case Files and Associated Records." See 71 Fed. Reg. 59,818 et seq. (Oct. 11, 2006). A copy of the notice may be obtained at the following link: http://www.justice.gov/ust/eo/rules_regulations/index.htm. Failure to provide this information could result in the dismissal or conversion of your bankruptcy case, or other action by the United States Trustee. 11 U.S.C. § 1112(b)(4)(F).

I declare under penalty of perjury that the foregoing Post-confirmation Report and its attachments, if any, are true and correct and that I have been authorized to sign this report.

/s/ William H. Henrich

Signature of Responsible Party

Liquidating Trustee of the Insys Liquidation Trust

Title

William H. Henrich


Printed Name of Responsible Party

04/14/2026


Date

Debtor's Name Insys Therapeutics, Inc.,


Case No. 19-11292



Page 1



Other Page 1



Page 2 Minus Tables

Bankruptcy Table 1-50

Debtor's Name Insys Therapeutics, Inc.,

Case No. 19-11292




Bankruptcy Table 51-100



Non-Bankruptcy Table 1-50



Non-Bankruptcy Table 51-100



Part 3, Part 4, Last Page